Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights

Marco Ardigò; Giuseppe Argenziano; Elena  Campione; Stefania Guida; Caterina  Longo; Giuseppe  Micali; Gianluca  Nazzaro; Ketty  Peris; Federico Venturi; Alessia  Villani; Iris  Zalaudek

doi:10.5826/dpc.1503a5921

Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights

Authors

Marco Ardigò Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
Giuseppe Argenziano Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
Elena Campione Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Stefania Guida Dermatology Clinic, IRCCS San Raffaele Hospital, Milan, Italy
Caterina Longo Skin Cancer Center, Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia, Reggio Emilia, Italy; Dermatology Department, University of Modena and Reggio Emilia, Italy
Giuseppe Micali Dermatology Clinic, University of Catania, Catania, Italy
Gianluca Nazzaro Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Physiopathology and Transplantation, University of Milan, Italy
Ketty Peris Dermatology, Department of Medical Science and Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
Federico Venturi Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
Alessia Villani Dermatology Section, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
Iris Zalaudek Department of Dermatology and Venereology, University of Trieste, Trieste, Italy

Keywords:

Actinic Keratosis, tirbanibulin, expert opinion, topical treatment

Abstract

Introduction: Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.

Objectives: The aim of this article is to deliver advice, via expert consensus, on optimal use of tirbanibulin in the real-life management of AK.

Methods: A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients, based on selected literature data and their own clinical experience.

Results: Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements were elaborated and voted, concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities and key messages for patient communication.

Conclusion: Tirbanibulin should be considered as a first-line option for most patients with AK, owing to its proven efficacy, good local and systemic tolerability and a short treatment regimen of 5 days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also makes it possible to use flexible therapeutic schedules, including repeated treatment cycles, if needed.

References

Kandolf L, Peris K, Malvehy J, et al; European Association of Dermato‐Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes). European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes). J Eur Acad Dermatol Venereol. 2024;38(6):1024-1047. DOI: 10.1111/jdv.19897. PMID: 38451047.

Malvehy J, Stratigos AJ, Bagot M, Stockfleth E, Ezzedine K, Delarue A. Actinic keratosis: Current challenges and unanswered questions. J Eur Acad Dermatol Venereol. 2024;38 Suppl 5:3-11. DOI: 10.1111/jdv.19559. PMID: 38923589.

Valenti M, Bianco M, Narcisi A, Costanzo A, Borroni R, Ardigò M. Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment. Dermatol Pract Concept. 2024;14(3 S1). DOI: 10.5826/dpc.1403S1a145S. PMID: 39133636.

Arcuri D, Ramchatesingh B, Lagacé F, et al. Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. Int J Mol Sci. 2023;24(5):4989. DOI: 10.3390/ijms24054989. PMID: 36902419.

Aggarwal I, Puyana C, Chandan N, Jetter N, Tsoukas M. Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review. Am J Clin Dermatol. 2024;25(3):391-405. DOI: 10.1007/s40257-023-00839-8. PMID: 38351246.

Dao DD, Sahni VN, Sahni DR, Balogh EA, Grada A, Feldman SR. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses. Ann Pharmacother. 2022;56(4):494-500. DOI: 10.1177/10600280211031329. PMID: 34301153.

Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022;87(2):373-374.e5. DOI: 10.1016/j.jaad.2022.04.013. PMID: 35439607.

Blauvelt A, Kempers S, Lain E, et al; Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520. DOI: 10.1056/NEJMoa2024040. PMID: 33567191.

Nazzaro G, Carugno A, Bortoluzzi P, et al. Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients. Int J Dermatol. 2024;63(11):1566-1574. DOI: 10.1111/ijd.17168. PMID: 38605473.

Campione E, Rivieccio A, Gaeta Shumak R, et al. Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals (Basel). 2023;16(12):1686. DOI: 10.3390/ph16121686. PMID: 38139813.

Kirchberger MC, Gfesser M, Erdmann M, Schliep S, Berking C, Heppt MV. Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study. J Clin Med. 2023;12(14):4837. DOI: 10.3390/jcm12144837. PMID: 37510952.

Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209-e233. DOI: 10.1016/j.jaad.2021.02.082. PMID: 33820677.

Sinclair R, Baker C, Spelman L, Supranowicz M, MacMahon B. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies. Australas J Dermatol. 2021;62(2):119-123. DOI: 10.1111/ajd.13447. PMID: 32840870.

Conforti C, Ambrosio L, Retrosi C, et al. Clinical and Dermoscopic Diagnosis of Actinic Keratosis. Dermatol Pract Concept. 2024;14(3 S1):e2024147S. DOI: 10.5826/dpc.1403S1a147S. PMID: 39133638.

Dréno B, Cerio R, Dirschka T, et al. A Novel Actinic Keratosis Field Assessment Scale for GradingActinic Keratosis Disease Severity. Acta Derm Venereol. 2017;97(9):1108-1113. DOI: 10.2340/00015555-2710. PMID: 28536731.

Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020;83(3):709-717. DOI: 10.1016/j.jaad.2020.03.126. PMID: 32387665.

Figueras Nart I, Cerio R, Dirschka T, et al; Progressing Evidence in AK (PEAK) Working Group. Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol. 2018;32(4):544-563. DOI: 10.1111/jdv.14652. PMID: 29055153.

Tan JM, Lambie D, Sinnya S, et al. Histopathology and reflectance confocal microscopy features of photodamaged skin and actinic keratosis. J Eur Acad Dermatol Venereol. 2016;30(11):1901-1911. DOI: 10.1111/jdv.13699. PMID: 27298142.

Szeimies RM, Ulrich C, Ferrándiz-Pulido C, et al. The "Personalising Actinic Keratosis Treatment for Immunocompromised Patients" (IM-PAKT) Project: An Expert Panel Opinion. Dermatol Ther (Heidelb). 2024;14(7):1739-1753. DOI: 10.1007/s13555-024-01215-y. PMID: 38902589.

Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5 Pt 1):738-43. DOI: 10.1016/0190-9622(91)70113-g. PMID: 1869646.

Zalaudek I, Giacomel J, Schmid K, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol. 2012;66(4):589-97. DOI: 10.1016/j.jaad.2011.02.011. PMID: 21839538.

Cinotti E, Tognetti L, Cartocci A, et al. Line-field confocal optical coherence tomography for actinic keratosis and squamous cell carcinoma: a descriptive study. Clin Exp Dermatol. 2021;46(8):1530-1541. DOI:10.1111/ced.14801PMID: 34115900.

Ruini C, Schuh S, Gust C, et al. In-Vivo LC-OCT Evaluation of the Downward Proliferation Pattern of Keratinocytes in Actinic Keratosis in Comparison with Histology: First Impressions from a Pilot Study. Cancers (Basel). 2021;13(12):2856. DOI: 10.3390/cancers13122856. PMID: 34201052.

Lacarrubba F, Verzì AE, Polita M, Aleo A, Micali G. Line-field confocal optical coherence tomography in the treatment monitoring of actinic keratosis with tirbanibulin: A pilot study. J Eur Acad Dermatol Venereol. 2023;37(9):e1131-e1133. DOI: 10.1111/jdv.19147. PMID: 37102431.

Venturi F, Veronesi G, Baraldi C, Dika E. Reflectance confocal microscopy as noninvasive tool for monitoring tirbanibulin efficacy in actinic keratosis. Photodiagnosis Photodyn Ther. 2024;48:104235. DOI: 10.1016/j.pdpdt.2024.104235. PMID: 38851311.

Morton C, Baharlou S, Basset-Seguin N, et al. Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project. Acta Derm Venereol. 2023;103:adv6229. DOI: 10.2340/actadv.v103.6229. PMID: 37289027.

de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176(1):20-43. DOI: 10.1111/bjd.15107. PMID: 28098380.

Ahmady S, Jansen MHE, Nelemans PJ, et al. Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2022;158(6):634-640. DOI: 10.1001/jamadermatol.2022.1034. PMID: 35475852.

Neugebauer R, Su KA, Zhu Z, et al. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. J Am Acad Dermatol. 2019;80(4):998-1005. DOI: 10.1016/j.jaad.2018.11.024. PMID: 30458208.

Pellacani G, Schlesinger T, Bhatia N, et al. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. J Eur Acad Dermatol Venereol. 2024;38 Suppl 1:3-15. DOI: 10.1111/jdv.19636. PMID: 38116638.

Iglesias-Puzas Á, Conde-Taboada A, Campos-Muñoz L, Sirgado-Martínez A, López-Bran E. 1% Tirbanibulin Ointment for Actinic Keratoses on Upper Extremities: A Retrospective Case Review Study. Acta Derm Venereol. 2023;103:adv15296. DOI: 10.2340/actadv.v103.15296. PMID: 37876333.

Schlesinger T. Commentary: Impact of Prior Treatment in the Efficacy and Tolerability of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies. J Clin Aesthet Dermatol. 2022;15(10 Suppl 1):S11-S12. PMID: 36408373.

Smolinski MP, Bu Y, Clements J, et al. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J Med Chem. 2018;61(11):4704-4719. DOI: 10.1021/acs.jmedchem.8b00164. PMID: 29617135.

Niu L, Yang J, Yan W, et al. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity. J Biol Chem. 2019;294(48):18099-18108. DOI: 10.1074/jbc.RA119.010732. PMID: 31628188.

Lacarrubba F, Verzì AE, Broggi G, Micali G. Line-field confocal optical coherence tomography shows in vivo apoptosis during a novel treatment for actinic keratosis: A histopathologic controlled study. J Eur Acad Dermatol Venereol. 2025;39(1):e60-e62. DOI: 10.1111/jdv.20106. PMID: 38752705.

Pariser DM. Approaches to Field Therapy for Actinic Keratoses: Relating Clinical Trial Results to Real-world Practice-A Commentary. J Clin Aesthet Dermatol. 2022;15(4):40-43. PMID: 35465033

Foley P, Stockfleth E, Peris K, et al. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatolog Treat. 2016;27(6):538-545. DOI: 10.1080/09546634.2016.1178372. PMID: 27161045.

Li Pomi F, Peterle L, d'Aloja A, Di Tano A, Vaccaro M, Borgia F. Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience. Dermatol Ther (Heidelb). 2024;14(6):1683-1696. DOI: 10.1007/s13555-024-01178-0. PMID: 38740726.

Li Pomi F, d'Aloja A, Rottura M, Vaccaro M, Borgia F. The Skin-Lightening Power of Tirbanibulin 1% Ointment. Dermatol Ther (Heidelb). 2025;15(1):95-110. DOI: 10.1007/s13555-024-01310-0. PMID: 39614963.

DuBois J, Jones TM, Lee MS, et al. Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal-Use Trial in Patients with Actinic Keratosis. Clin Pharmacol Drug Dev. 2024;13(2):208-218. DOI: 10.1002/cpdd.1368. PMID: 38185925.

Bhatia N, Lain E, Jarell A, et al. Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study. JAAD Int. 2024;17:6-14. DOI: 10.1016/j.jdin.2024.07.001. PMID: 39268198